Defective bone remodelling in osteoprotegerin-deficient mice

Journal of Electron Microscopy

Volumn 52, Issue 6, 2003, Pages 503-513

  Amizuka, Norio ^a,b   Shimomura, Junko ^a,b   Li, Minqi ^a,b   Seki, Yukie ^a,b   Oda, Kimimitsu ^a,b   Henderson, Janet E ^b,c   Mizuno, Atsuko ^d   Ozawa, Hidehiro ^e   Maeda, Takeyasu ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

Bone matrix; Bone remodelling; Osteoblast; Osteoclast; Osteoprotegerin; Ultrastructure

Indexed keywords

CELL RECEPTOR; GLYCOPROTEIN; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN; TNFRSF11B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; BONE MATRIX; BONE REMODELING; CONFOCAL MICROSCOPY; DISEASE MODEL; EPIPHYSIS; GENETICS; HUMAN; MOUSE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; TIBIA; ULTRASTRUCTURE;

ANIMALS; BONE MATRIX; BONE REMODELING; BONE RESORPTION; DISEASE MODELS, ANIMAL; EPIPHYSES; GLYCOPROTEINS; HUMANS; MICE; MICROSCOPY, CONFOCAL; OSTEITIS DEFORMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TIBIA;

ANIMALIA;

CEMENTS; MAMMALS; PHOSPHATASES;

BONE MATRIX; BONE REMODELLING; BONE RESORPTION; CALCEIN; CEMENT LINE; LABELINGS; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN; ULTRASTRUCTURE;

BONE;

EID: 0345832208     PISSN: 00220744     EISSN: None     Source Type: Journal    
DOI: 10.1093/jmicro/52.6.503     Document Type: Article

References (30)

1. Lacey D L, Timms E, Tan H L, Kelley M J, Dunstan C R, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, and Boyle W J (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, and Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
3. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, and Higashio K (1998) Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 246: 337-341.
4. Takahashi N, Udagawa N, Akatsu T, Tanaka H, Isogai Y, and Suda T (1991) Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 128: 1792-1796.
5. Amizuka N, Takahashi N, Udagawa N, Suda T, and Ozawa H (1997) An ultrastructural study of cell-cell contact between mouse spleen cells and calvaria-derived osteoblastic cells in a co-culture system for osteoclast formation. Acta Histochem. Cytochem. 30: 351-362.
6. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M T, and Martin T J (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrin. Rev. 20: 345-357.
7. Simonet W S, Lacey D L, Dunstan C R, Kelley M, Chang M S, Luthy R, Nguyen H Q, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L Hughes T M, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, and Boyle W J (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
8. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, and Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234: 137-142.
9. Min H, Morony S, Sarosi I, Dunstan C R, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik P J, Lacey D L, Boyle W J, and Simonet W S (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192: 463-474.
10. Shimizu-Ishiura M, Kawana F, and Sasaki T (2002) Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. J. Electron Microsc. 51: 315-325.
11. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, and Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247: 610-615.
12. Bucay N, Sarosi I, Dunstan C R, Morony S, Tarpley J, Capparelli C, Scully S, Tan H L, Xu W, Lacey D L, Boyle W J, and Simonet W S (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12: 1260-1268.
13. Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Boyle W J, and Riggs B L (2000) The roles of Osteoprotegerin and Osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15: 2-12.
14. Khosla S (2001) The OPG/RANKL/RANK system. Endocrinology 142: 5050-5055.
15. Baron R (1999) Anatomy and ultrastructure of bone. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed. Favus M J, pp. 3-10, (Lippincott Williams & Wilkins, Philadelphia).
16. Whyte M P, Obrecht S E, Finnegan P M, Jones J L, Podgornik M N, McAlister W H, and Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347: 175-184.
17. Amizuka N, Karaplis A C, Henderson J E, Warshawsky H, Lipman M L, Matsuki Y, Ejiri S, Tanaka M, Izumi N, Ozawa H, and Goltzman D (1996) Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev. Biol. 175: 166-176.
18. Villanueva A R (1974) A bone stain for osteoid seams in fresh, unembedded, mineralized sections of bone. Stain Technol 49: 1-8.
19. Villanueva A R and Lundin K D (1989) A versatile new mineralized bone stain for simultaneous assessment of tetracycline and osteoid seams. Stain Technol. 64: 129-138.
20. Amizuka N, Yamada M, Watanabe J, Hoshi K, Fukushi M, Oda K, Ikehara Y and Ozawa H (1998) Morphological examination of bone synthesis via direct administration of basic fibroblast growth factor into rat bone marrow. Microsc. Res. Tech. 41: 313-322.
21. Oda K, Amaya Y Fukushi-Irie M, Kinameri Y Ohsuye K, Kubota I, Fujimura S, and Kobayashi J (1999) A general method for rapid purification of soluble versions of glycosylphosphatidylinositol-anchored proteins expressed in insect cells: an application for human tissue-nonspecific alkaline phosphatase. J. Biochem. 126: 694-699.
22. Burstein A, Zika J C, Heiple K G, and Klein L (1977) Contribution of collagen and mineral to the elastic-plastic properties of bone. J. Bone J. Surg. 57A: 956-961.
23. Bonadio J, Saunders T L, Tsai E, Goldstein S A, Morris-Wiman J, Brinkley L, Dolan D F Altschuler R A, Hawkins J E Jr, Bateman J F Mascara T, and Jaenisch R (1990) Transgenic mouse model of the mild dominant form of osteogenesis imperfecta. Proc. Natl. Acad. Sci. USA 87: 7145-7149.
24. Bonadio J, Jepsen K J, Mansoura M K, Jaenisch R, Kuhn J L, and Goldstein S A (1993) A murine skeletal adaptation that significantly increases cortical bone mechanical properties. Implications for human skeletal fragility. J. Clin. Invest. 92: 1697-1705.
25. Burr D B, Schaffler M B, and Frederickson R G (1988) Composition of the cement line and its possible mechanical role as a local interface in human compact bone. J. Biochem. 21: 939-945.
26. McKee M D, Farach-Carson M C, Butler W T, Hauschka P V, and Nanci A (1993) Ultrastructural immunolocalization of noncollagenous (osteopontin and osteocalcin) and plasma (albumin and alpha 2HS-glycoprotein) proteins in rat bone. J. Bone Miner. Res. 8: 485-496.
27. McKee M D and Nanci A (1996) Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc. Res. Tech. 33: 141-164
28. McKee M D and Nanci A (1996) Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect. Tissue Res. 35: 197-205.
29. McKee M D and Nanci A (1996) Osteopontin deposition in remodeling bone: an osteoblast mediated event. J. Bone Miner. Res. 11: 873-875.
30. Cullinane D M and Einhorn T A (2002) Biomechanics of Bone. In: Principles of Bone Biology, eds Bilezikian J P, Raisz L G, and Rodan G A, pp. 17-32, (Academic Press, New York).